About Us

Reimagining
cardiovascular health

A new approach for cardiovascular risk stratification
with smart imaging biomarkers

Mission

Improve the use of imaging biomarkers in cardiovascular care, enabling a precise & personalized understanding of patient’s cardiovascular risk.

Origin

The IMAGEENS project initiated in Paris, with a focus on the prevention and early diagnosis of cardiovascular diseases (CVD)
From its origin, IMAGEENS was plunged in international DeepTech and was designed to fully leverage the potential of MRI-derived arterial stiffness biomarkers across multiple clinical applications addressing unmet needs in primary and secondary cardiovascular prevention markets.
IMAGEENS is based on one of the world’s most published and clinically validated technologies for the analysis of arterial function using MRI. It leverages the ArtFun technology, which was validated through the world-renowned MESA clinical study led by Johns Hopkins University and sponsored by the NIH, involving 3,675 patients followed over 8.5 years.
The technology has been recognized through several prestigious French innovation competitions and multiple innovation labels. It also has supported more than 75 scientific publications in collaboration with leading cardiovascular experts across a broad range of clinical applications, contributing to a deeper understanding of cardiovascular diseases.

Highlights

2017
Imageens Launched
2018
Pioneering MRI-derived arterial stifness biomarkers
2019
Build The Technology
2020
Fueling Cardiovascular Research with our Biomarkers
2021
Publishing Research Findings
2022
First collaboration with Pharma company
2023
Deployement In Europe
2024
Deployement in North Africa
2025
Deployement in MENA region

Awards

They trusted Us

Powered by a diverse team of experienced innovators, scientist, and cardiovascular imaging experts , combining scientific excellence, clinical expertise, and technological innovation.

Excited about the project ?

Reach out to us